Table 1 Characteristics of patients with metastatic thyroid cancer to the lung treated with TKI by cavitation status
From: Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
Covariate | Entire cohort (NÂ =Â 83,%) | Cavitation (NÂ =Â 10,%) | No cavitation (NÂ =Â 73,%) | P-value |
|---|---|---|---|---|
Male, no. | 39 (47%) | 4 (40%) | 35 (47.9) | 0.637 |
Age, mean ± standard deviation | 60.9 ± 13.4 years | 64.9 ± 6.5 years | 60.39 ± 14.0 years | 0.317 |
Race/ethnicity, no. | 0.313 | |||
 White | 50 (60%) | 5 (50%) | 45 (61.6%) | |
 Black | 8 (9.6%) | 0 (0.0%) | 8 (11%) | |
 Hispanic | 17 (20.5%) | 3 (30%) | 14 (19%) | |
 Asian | 7 (8.4%) | 2 (20%) | 5 (6.8%) | |
Cancer type, no. | 0.068 | |||
 Papillary | 39 (47%) | 7 (70%) | 32 (43.8%) | |
 Follicular | 6 (7.2%) | 2 (20%) | 4 (5.4%) | |
 Poorly differentiated/anaplastic | 26 (31.3%) | 1 (10%) | 25 (34.2%) | |
 Other | 12 (14.4%) | 0 (0.0%) | 12 (16.4%) | |
Pleural base lesions on imaging, no. | 15 (18%) | 4 (40%) | 11 (15%) | 0.055 |
Emphysema on imaging, no. | 6 (7.2%) | 0 (0.0%) | 6 (8.2%) | 0.347 |
Prior radiation to the chest, no. | 2 (2.4%) | 0 (0.0%) | 2 (2.7%) | 0.596 |
Drug used, no. | 0.579 | |||
 Lenvatinib | 68 (82%) | 7 (70%) | 61 (83.5%) | |
 Sorafenib and lenvatinib | 10 (12%) | 2 (20%) | 8 (11%) | |
 Other | 5 (6%) | 1 (10%) | 4 (5.4%) | |
Lung metastasis responded to TKI, no. | 37 (44.5%) | 6 (60%) | 31 (42.4%) | 0.295 |